November 24th, 2015

Donate a Photo Kicks Off the Giving Season in a Big Way

Donate a Photo

We’re in Times Square in New York City today, kicking off the giving season by celebrating the power of giving back. Johnson & Johnson employees, along with several of our philanthropic partners, are hosting an immersive experience to showcase Donate a Photo, our free app that takes a simple photo and turns it into a way to help those in need.

Inside the Donate a Photo tent at today’s event, attendees can learn about the meaningful work our partners – Save the Children, USO, Operation Smile, and Girl Up – are doing here in the U.S. and around the world to improve the health and lives of families. There are photo stations to take and donate photos, along with an interactive mosaic that tracks the real-time impact the photos from the event are making.

You don’t have to be in New York City today to join the Donate a Photo movement. You can help care for the world wherever you are by downloading Donate A Photo, snapping a photo and selecting a cause that you want to help. Share your photo on your social networks to get your friends and family involved, multiplying the good you can do with the snap of a shutter.

Read More

November 19th, 2015

Building Inclusive Economies, Building a Better World

By Christoph Glaetzer, Vice President Strategic Marketing & Market Access, Janssen, pharmaceutical companies of Johnson & Johnson, Asia Pacific

There is a well-known proverb that says if you want to walk fast, walk alone; but if you want to go far, go together. It is something that I reflected upon a lot this week, while attending the annual Asia-Pacific Economic Cooperation (APEC) CEO Summit in Manila, the Philippines.

The Philippines’ government launched their APEC host year with the ambitious theme of ‘Building Inclusive Economies, Building a Better World.’ The success of this strategy was contingent on ‘involving and integrating the majority of the population in the economic and social mainstream.’ It is an ambition that requires people to be healthy, employed and able to contribute, and to be supported by fully functioning health systems. It also requires people to walk together, and there were plenty of great examples of that this week in Manila.

We have seen much progress across the APEC region in support of this strategy, and the leadership of the Philippines’ government, together with the APEC Health Working Group and Life Sciences Innovation Forum (LSIF), in the development of an APEC Healthy Asia Pacific 2020 Roadmap is commendable.

Read More

November 19th, 2015

How We Are Helping the Syrian Humanitarian Crisis

Earlier this week, at at the third annual Save the Children Illumination Gala, we were proud to announce a new donation of $1.75 million dollars to provide immediate humanitarian aid and longer-term resilience training to Syrian refugees, many of whom are children who have fled the country and are growing up in refugee camps with uncertain futures.

Below, a breakdown of the heartbreaking stats and how we are showing our care.


Read More

November 18th, 2015

Changing the World Starts with the First Few Minutes

By Joaquin Duato, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson

It will take you only about three minutes to read this blog post. Three minutes may seem short, but it is long enough for lives to change.

In the next three minutes:

  • Six babies will die from failing to take their first breath.
  • More than 60 children under five years of age will die from largely preventable diseases.
  • Seven more refugees will flee across the Syrian border.

The good news though is that three minutes is all it can take to change a life for the better.

  • In three minutes a nurse can be enrolled in our Helping Babies Breathe program in Uganda, Malawi or Ethiopia. This program is a key component of our $10 million, three year partnership with Save the Children (STC). Focused on the first ‘golden minute’ of a baby’s life, the program has to date helped save more than 15,000 newborn lives.
  • It also only takes three minutes to show a new mother how to make bath time a pivotal brain-building moment for her newborn. This is just one of many skills under-served mothers in the U.S. can learn through another of our programs with STC – the Early Steps to School success program.

Read More

November 18th, 2015

A New Chance for Patients with Advanced Multiple Myeloma


Today, we’re building on our unwavering commitment to transform cancer into a manageable and eventually curable disease.

Multiple myeloma is a blood cancer that affects plasma cells, a type of white blood cell. In multiple myeloma, plasma cells become cancerous and grow uncontrollably in the bone marrow. These cells form tumors in the bone and weaken the immune system. It is a rare, incurable cancer. Only half of patients survive five years after their initial diagnosis.

More than a decade ago, we began to build our heritage in multiple myeloma with the introduction of VELCADE®. But despite tremendous progress over the years in the treatment of multiple myeloma, an unmet need still remains. Unfortunately, people living with this cancer who don’t respond or relapse after treatment typically have poor prognoses and few remaining options. Janssen Oncology is committed to developing novel therapies for people living with hard-to-treat cancers, such as multiple myeloma.

DARZALEX™ (daratumumab) is a testament to this commitment. We are pleased to announce that the FDA has approved DARZALEX for patients whose multiple myeloma has relapsed, or who are no longer responding to current therapies.

With DARZALEX, we have a new immunotherapy option for U.S. patients who aren’t responding to treatment or whose cancer has progressed while on their current therapy.

Read More

November 12th, 2015

Sterkins 1

Boundaries can drive our personal and professional growth

By Kris Sterkens, Company Group Chairman, Janssen, pharmaceutical companies of Johnson & Johnson, Asia Pacific

A major challenge for business leaders in Asia is evaluating the amount of time that employees devote to their work. Indeed, in this year’s triannual UBS Prices and Earnings Report, four of the top five cities with the highest annual working hours are in Asia. And for many, remaining contactable all day, every day, including weekends and holidays, is a badge of honor.

I constantly question whether these hours translate into better productivity.

Excessive working hours can be a sign of inefficiency that is caused by the need to develop new capabilities. More urgently, this excess can often lead to employee burn-out, which not only puts talent retention at risk but also inhibits innovative thinking.

A recent Catalyst survey found that the majority of high-potential employees across Asia don’t aspire to top roles in their organizations because of the perceived pressure, stress and long hours.

If we want to develop today’s local talent into tomorrow’s global leaders, we must redefine the requirements of leadership. We must demonstrate that self-awareness, full engagement and boundaries will allow everyone at any level to fully indulge in both their professional and personal journeys.

Read More

November 5th, 2015

Demand Diversity, Embrace Innovation

By Martin Fitchet, M.D., Global Head, Research & Development, Johnson & Johnson Medical Devices Companies

Editor’s Note: Here at our Johnson & Johnson corporate blog, we occasionally like to share speech excerpts delivered by members of our senior leadership team at conferences and industry events. On Friday, November 6, Martin Fitchet, M.D., Global Head, Research & Development, Johnson & Johnson Medical Devices Companies, spoke at the Net Impact conference in Seattle. Martin shared his own personal and professional evolution as a scientist and gay man during his “Demand Diversity, Embrace Innovation” spotlight talk. Martin’s view- that diversity and innovation are inseparably linked- dovetails with our mission at J&J to cultivate a diverse workforce in order to unleash the power of innovative thinking and create healthcare breakthroughs that help millions of people around the world. We invite you to read excerpts of his remarks and be inspired by them.

Martin Fitchet

Living Your Own Truth:

I am a senior scientist at the largest health care company in the world. I am also gay. I do not say that because I want to make who I am the centerpiece of my time with you today. I don’t. I’m much more interested in who you are.

Read More

November 4th, 2015

Exploring the Secret World Inside Us… Janssen and the Microbiome

By Dirk Gevers, Global Head, Janssen Human Microbiome Institute at Janssen Research & Development, LLC

Dirk Gevers - Microbiome

Each of us has a secret world inside us, on us and around us. At the time of birth, our bodies are exposed to a wildly diverse world of microbes and soon after, a complex, personal population of these microorganisms and their genetic impressions – our microbiome – starts to develop. Using similar methods that once decoded the human genome, the scientific community has begun to more deeply understand the role the microbiome plays in keeping us healthy, and how it may influence the development of illness and disease.

Unlocking the mysteries of the microbiome has been my passion for nearly a decade. From my time participating in the NIH Human Microbiome Project to my new position as the Global Head of the Janssen Human Microbiome Institute (JHMI), my focus has been on understanding how balance and imbalance in the microbiota, or our “bugs,” can be assessed and linked to diseases with devastating effects, like cancer, inflammatory bowel diseases and diabetes. At the JHMI, we are committed to finding new solutions or interventions targeting the microbiome that can promote health. By building our internal expertise and developing an open innovation approach, we will aim to work with scientific and entrepreneurial collaborators around the world across academia, government and the life science industry who share our passion.

Read More

October 28th, 2015

Janssen Recognizes World Psoriasis Day

This October 29th, the Janssen Pharmaceutical Companies of Johnson & Johnson join the International Federation of Psoriasis Associations in support of World Psoriasis Day, an annual event dedicated to raising awareness of an autoimmune disease that affects 125 million people worldwide.

At Janssen, our commitment to people living with psoriatic disease has never been stronger, both through the medicines that we offer today and through our continued research and development to advance the next generation of therapies for the future.

We are motivated to go further by the personal impact of psoriasis and psoriatic arthritis, pursuing approaches that will hopefully one day intercept and even prevent psoriatic disease altogether.

Every day, these efforts bring us closer to realizing our vision of #aworldfreefrom immune and inflammatory diseases, an aspirational goal but one that we believe is achievable for people living with or who may develop psoriatic disease in the future.

Anne Fourie2

Anne Fourie, PhD, is Disease Area Leader, Psoriasis, Janssen Research & Development, LLC



irene HsuIrene Hsu, PharmD, MBA, is Vice President, Commercial Disease Area Leader, Rheumatoid Arthritis and Psoriasis, Janssen Pharmaceutical Companies of Johnson & Johnson.




Read More

October 23rd, 2015

Advancing human health: Decoding the Human Immune System

By Johan Van Hoof, M.D., Global Therapeutic Area Head, Infectious Disease & Vaccines, Janssen Pharmaceutical Companies of Johnson & Johnson

Johan Van Hoof

Earlier this year I travelled to Sierra Leone and witnessed the devastation that Ebola was inflicting on the people of that country.  Before Ebola, Sierra Leone had one of the fastest growing economies in Africa, well on its way to recovering from a lengthy civil war.  People’s aspirations were high.   Ebola halted that.  And, it wreaked havoc and fear across the entire world, reminding us, how susceptible human life is to the devastating effects of infectious diseases and how much we still have to learn about how best to stimulate our immune system to prevent them.

That’s why today I am proud that we are joining the Human Vaccines Project.  Much like the Human Genome Project, the effort to map and sequence the blueprint of a human being, the Human Vaccines Project attempts to decode the human immunome—the human immune system.

Thanks to the Human Genome Project we are now able to identify the genetic mechanisms underlying disease and have the tools we need to more accurately diagnose, treat, prevent and cure diseases launching an era of personalized medicine.   Likewise, the Cancer Genome Project, which catalogs all known mutations to better understand the molecular basis of this disease, provides use with techniques to improve cancer diagnosis, treatment, and prevention.

Read More